Since BioAgri has made a breakthrough in gene-transfer technology to generate transgenic chickens for producing therapeutic protein from eggs, we are now concentrating our business in:

(1) Manufacturing contract service for
     pharmaceutical and biotechnology
     companies’ research and clinical trials

BioAgri provides manufacturing contract service to produce large quantities of human therapeutic proteins from chicken egg whites under cGMP process standards with a 10-fold lower cost than mammalian cell fermentation. 

(2) New protein drug development

We are biomanufacturing alpha-1 antitrypsin from transgenic chicken eggs for alpha-1 antitrypsin deficiency (AAT deficiency) treatment, which is one of three lethal inherited disorders among Caucasians, the other two common lethal genetic defects being cystic fibrosis and Down syndrome. This genetic defect afflicts one per 3000-5000 individuals; 160,000-200,000 patients in the US and Western Europe are suffering from this disease. Alpha-1 antitrypsin deficiency has been characterized by a marked reduction in serum levels of a naturally occurring protein called alpha-1 antitrypsin (also known as AAT) that causes emphysema, cirrhosis, and/or panniculitus. From estimates, a patient would have to receive 6 g AAT/per week to maintain the normal level in blood. The current manufacturing capacity in bacteria, yeast and mammalian cell fermentation is unlikely to meet this requirement. Our transgenic chicken technology should be able to manufacture large enough quantities for AAT deficiency treatment. 

(3) Biogeneric drug development

In our generic therapeutic protein program, we have already proceeded to manufacture a few patent-expired therapeutic proteins and expect to enter into clinical trials in the next few years. We have formed a joint venture with BioProMed, a biotech company in Taiwan, and are negotiating partnerships with other pharmaceutical companies worldwide to co-develop and market low cost generic human therapeutic proteins with our transgenic chicken process.